Dynavax Technologies Corporation (DVAX)

$11.43

-0.06

(-0.52%)▲

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Dynavax Technologies Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 69.51M → 55.59M (in $), with an average decrease of 20.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 14.29M → 219.0K (in $), with an average decrease of 98.5% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 27.7% return, outperforming this stock by 25.6%

Performance

  • $11.35
    $11.51
    $11.43
    downward going graph

    0.74%

    Downside

    Day's Volatility :1.43%

    Upside

    0.7%

    downward going graph
  • $10.06
    $15.15
    $11.43
    downward going graph

    11.99%

    Downside

    52 Weeks Volatility :33.6%

    Upside

    24.55%

    downward going graph

Returns

PeriodDynavax Technologies CorporationSector (Health Care)Index (Russel 2000)
3 Months
-17.87%
-0.5%
0.0%
6 Months
-20.32%
5.9%
0.0%
1 Year
2.13%
3.1%
-1.9%
3 Years
41.68%
14.2%
-21.8%

Highlights

Market Capitalization
1.5B
Book Value
$4.8
Earnings Per Share (EPS)
-0.05
PEG Ratio
0.0
Wall Street Target Price
25.75
Profit Margin
-2.75%
Operating Margin TTM
-11.69%
Return On Assets TTM
-1.92%
Return On Equity TTM
-1.06%
Revenue TTM
232.3M
Revenue Per Share TTM
1.8
Quarterly Revenue Growth YOY
-69.89999999999999%
Gross Profit TTM
448.2M
EBITDA
-26.1M
Diluted Eps TTM
-0.05
Quarterly Earnings Growth YOY
-0.76
EPS Estimate Current Year
0.26
EPS Estimate Next Year
0.51
EPS Estimate Current Quarter
-0.01
EPS Estimate Next Quarter
0.02

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Dynavax Technologies Corporation(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 125.28%

Current $11.43
Target $25.75

Company Financials

FY18Y/Y Change
Revenue
8.2M
↑ 2407.03%
Net Income
-158.9M
↑ 66.99%
Net Profit Margin
-1.9K%
↑ 27160.81%
FY19Y/Y Change
Revenue
35.2M
↑ 329.6%
Net Income
-151.4M
↓ 4.72%
Net Profit Margin
-429.87%
↑ 1508.4%
FY20Y/Y Change
Revenue
46.6M
↑ 32.18%
Net Income
-91.8M
↓ 39.38%
Net Profit Margin
-197.15%
↑ 232.72%
FY21Y/Y Change
Revenue
439.4M
↑ 844.0%
Net Income
76.7M
↓ 183.59%
Net Profit Margin
17.46%
↑ 214.61%
FY22Y/Y Change
Revenue
722.7M
↑ 64.45%
Net Income
293.2M
↑ 282.15%
Net Profit Margin
40.56%
↑ 23.1%
FY23Y/Y Change
Revenue
232.3M
↓ 67.86%
Net Income
-6.4M
↓ 102.18%
Net Profit Margin
-2.75%
↓ 43.31%
Q3 FY22Q/Q Change
Revenue
167.7M
↓ 34.6%
Net Income
63.8M
↓ 50.44%
Net Profit Margin
38.04%
↓ 12.16%
Q4 FY22Q/Q Change
Revenue
184.5M
↑ 9.99%
Net Income
67.7M
↑ 6.15%
Net Profit Margin
36.71%
↓ 1.33%
Q1 FY23Q/Q Change
Revenue
46.9M
↓ 74.57%
Net Income
-24.3M
↓ 135.92%
Net Profit Margin
-51.85%
↓ 88.56%
Q2 FY23Q/Q Change
Revenue
60.2M
↑ 28.39%
Net Income
3.4M
↓ 114.1%
Net Profit Margin
5.69%
↑ 57.54%
Q3 FY23Q/Q Change
Revenue
69.5M
↑ 15.38%
Net Income
14.3M
↑ 316.58%
Net Profit Margin
20.56%
↑ 14.87%
Q4 FY23Q/Q Change
Revenue
55.6M
↓ 20.02%
Net Income
219.0K
↓ 98.47%
Net Profit Margin
0.39%
↓ 20.17%
FY18Y/Y Change
Total Assets
210.9M
↓ 3.61%
Total Liabilities
147.8M
↑ 668.45%
FY19Y/Y Change
Total Assets
279.1M
↑ 32.33%
Total Liabilities
270.8M
↑ 83.18%
FY20Y/Y Change
Total Assets
353.3M
↑ 26.59%
Total Liabilities
294.6M
↑ 8.79%
FY21Y/Y Change
Total Assets
1.0B
↑ 194.18%
Total Liabilities
816.9M
↑ 177.3%
FY22Y/Y Change
Total Assets
985.9M
↓ 5.14%
Total Liabilities
404.8M
↓ 50.44%
FY23Y/Y Change
Total Assets
997.1M
↑ 1.14%
Total Liabilities
375.0M
↓ 7.36%
Q3 FY22Q/Q Change
Total Assets
999.3M
↓ 2.31%
Total Liabilities
498.8M
↓ 16.9%
Q4 FY22Q/Q Change
Total Assets
985.9M
↓ 1.35%
Total Liabilities
404.8M
↓ 18.83%
Q1 FY23Q/Q Change
Total Assets
969.9M
↓ 1.62%
Total Liabilities
406.2M
↑ 0.33%
Q2 FY23Q/Q Change
Total Assets
936.4M
↓ 3.45%
Total Liabilities
359.2M
↓ 11.56%
Q3 FY23Q/Q Change
Total Assets
972.9M
↑ 3.9%
Total Liabilities
368.0M
↑ 2.45%
Q4 FY23Q/Q Change
Total Assets
997.1M
↑ 2.48%
Total Liabilities
375.0M
↑ 1.9%
FY18Y/Y Change
Operating Cash Flow
-131.3M
↑ 69.38%
Investing Cash Flow
55.5M
↓ 151.03%
Financing Cash Flow
99.1M
↓ 47.26%
FY19Y/Y Change
Operating Cash Flow
-121.3M
↓ 7.65%
Investing Cash Flow
-42.8M
↓ 177.13%
Financing Cash Flow
154.4M
↑ 55.8%
FY20Y/Y Change
Operating Cash Flow
-92.3M
↓ 23.92%
Investing Cash Flow
-26.5M
↓ 37.98%
Financing Cash Flow
109.5M
↓ 29.06%
FY21Y/Y Change
Operating Cash Flow
335.5M
↓ 463.71%
Investing Cash Flow
14.2M
↓ 153.61%
Financing Cash Flow
55.8M
↓ 49.06%
FY22Y/Y Change
Operating Cash Flow
62.7M
↓ 81.31%
Investing Cash Flow
-316.0M
↓ 2321.41%
Financing Cash Flow
19.5M
↓ 64.99%
Q3 FY22Q/Q Change
Operating Cash Flow
61.6M
↑ 269.71%
Investing Cash Flow
-119.0M
↓ 326.75%
Financing Cash Flow
8.1M
↑ 683.75%
Q4 FY22Q/Q Change
Operating Cash Flow
34.9M
↓ 43.23%
Investing Cash Flow
-33.0M
↓ 72.31%
Financing Cash Flow
153.0K
↓ 98.1%
Q1 FY23Q/Q Change
Operating Cash Flow
27.6M
↓ 20.96%
Investing Cash Flow
-52.3M
↑ 58.75%
Financing Cash Flow
-3.1M
↓ 2119.61%
Q2 FY23Q/Q Change
Operating Cash Flow
28.0M
↑ 1.54%
Investing Cash Flow
24.7M
↓ 147.24%
Financing Cash Flow
-294.0K
↓ 90.49%
Q3 FY23Q/Q Change
Operating Cash Flow
31.1M
↑ 10.99%
Investing Cash Flow
-106.1M
↓ 529.07%
Financing Cash Flow
3.0M
↓ 1118.37%

Technicals Summary

Sell

Neutral

Buy

Dynavax Technologies Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dynavax Technologies Corporation
Dynavax Technologies Corporation
-1.79%
-20.32%
2.13%
41.68%
41.68%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.63%
16.46%
27.73%
40.21%
63.9%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.25%
-2.88%
-6.68%
9.31%
9.31%
Zoetis Inc.
Zoetis Inc.
-10.35%
-12.19%
-12.37%
-8.97%
56.17%
Viatris Inc.
Viatris Inc.
-5.44%
17.92%
12.21%
-16.08%
-31.95%
Catalent, Inc.
Catalent, Inc.
-0.32%
22.03%
22.78%
-48.65%
30.48%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dynavax Technologies Corporation
Dynavax Technologies Corporation
31.59
NA
0.0
0.26
-0.01
-0.02
NA
4.8
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
54.74
54.74
0.44
4.69
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.79
28.79
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.48
29.48
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
226.4
226.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dynavax Technologies Corporation
Dynavax Technologies Corporation
Buy
$1.5B
41.68%
31.59
-2.75%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.5B
63.9%
54.74
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.0B
9.31%
28.79
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.5B
56.17%
29.48
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-31.95%
226.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
30.48%
211.02
-31.77%

Institutional Holdings

  • BlackRock Inc

    17.91%

  • Federated Hermes Inc

    8.70%

  • State Street Corporation

    7.27%

  • Vanguard Group Inc

    7.10%

  • Goldman Sachs Group Inc

    5.51%

  • Deep Track Capital, LP

    5.43%

Company Information

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

Organization
Dynavax Technologies Corporation
Employees
408
CEO
Mr. Ryan Spencer
Industry
Health Technology

Discover More

FAQs